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Appendix 1: Results of the interrupted time series analysis 
Results of the segmented linear regression, which divides a time series into pre- and 
post-intervention portions. As the routine infant seven-valent pneumococcal 
conjugate vaccine programme was introduced in September 2006 with a campaign 
for those under the age of 2 years, we chose 2006-07 as the intersection between 
segments (i.e., the intervention). The graph displays the incidence of hospitalisation 
for all cause pneumonia before and after the introduction of the seven-valent 
pneumococcal conjugate vaccine, and Table 1 shows the results of the regression 
analysis. Over the time period there was a general trend for an increase in 
hospitalisations for pneumonia in children under 5 years of age in both high and low 
risk groups. In the low risk group the introduction of the seven-valent pneumococcal 
conjugate vaccine is associated with an immediate and significant reduction in 
incidence, while such a significant reduction was not observed in the high-risk group. 
Furthermore, during the post intervention period the incidence in the low risk group 
did not significantly change while in the high risk group an increase was observed 
(although also not significant p=0.07) 
 
Appendix 1, Figure 1. Comparison in the incidence trend of hospitalized pneumonia in low-risk and high 
risk individuals (eligible for the 7-valent pneumococcal conjugate vaccine ) before and after the 
introduction of 7-valent pneumococcal conjugate vaccine. 
 
The expected annual incidence of hospitalisations for non-bacteraemic pneumonia Yi, 
is modelled using multiple linear regression. The final model was: 
Yi = B0 + B1*T + B2*D + B3*P  
Where T is time (in years) since the start of the observation period, D is a dummy 
variable indicating pre- or post-vaccination period (coded 0 prior to intervention, and 
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1 otherwise) and P is the time since vaccination, where time prior to vaccination is 
coded 0. 
Appendix 1 Table 1, showing the outcome of the model for seven-valent pneumococcal conjugate vaccine eligible 
children (less than 5 years of age) 
 Coefficients 
Standard 
Error t Statistics P-value 
Low risk children (<5 years of age) 
Intercept, B0 240.78 11.89 20.25 <0.01 
Overall trend <5 years, B1 9.10 2.11 4.31 <0.01 
Change in level after vacc, <5 years, B2 -56.81 22.43 -2.53 0.03 
Difference in trend post- intervention <5 years, B3 -0.41 7.62 -0.05 0.96 
     
High risk children (<5 years of age) 
Intercept, B0 221.58 19.10 11.60 <0.01 
Overall trend <5 years, B1 18.51 3.39 5.45 0.00 
Change in level after vacc, <5 years, B2 -47.95 36.04 -1.33 0.22 
Difference in trend post- intervention <5 years, B3 25.68 12.24 2.10 0.07 
 
 
 
The incidence and case fatality ratio of non-bacteraemic pneumonia are shown in 
table 2.  
 
Appendix 1, Table 2, showing the incidence, case fatality ratios of non- bacteraemic pneumonia. 
Age group Incidence per 100,000 
(2009/10) 
Case fatality ratios Share of pneumococcal non- bacteraemic 
pneumonia which are 13-valent pneumococcal 
conjugate vaccine serotypes 
2-4 270 
1.5% 
Similar to invasive pneumococcal disease  see 
Appendix 2 
5-14 62 
2.6% 
Similar to invasive pneumococcal disease  see 
Appendix 2 
15-44 218 
10.8% 
Similar to invasive pneumococcal disease  see 
Appendix 2 
45-64 744 
17.8% 
Similar to invasive pneumococcal disease  see 
Appendix 2 
65+ 2883 
34.1% 
Similar to invasive pneumococcal disease  see 
Appendix 2 
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Appendix 2: Poisson regression model to predict the future reduction in VT 
invasive pneumococcal disease  
To predict the future reduction in invasive pneumococcal disease due to vaccine 
serotypes we fitted Poisson regression models to the corrected number of incident 
culture confirmed invasive pneumococcal disease  cases due to vaccine serotypes 
for the post seven-valent pneumococcal conjugate vaccine period to the total number 
of invasive pneumococcal disease cases in yr 0 including PCR positives. We 
assumed that the number of incident cases is a variable with a Poisson distribution 
that has a mean depending on the explanatory variable, time (after the introduction of 
the infant seven-valent pneumococcal conjugate vaccine programme). Numbers of 
cases were obtained from a recently published study by our group1 and data 
regarding the population size were obtained from the Office for National Statistics2. 
The models were estimated using the maximum likelihood method, while exact 
confidence intervals were calculated using the standard chi-square intervals. We 
projected the estimates for a maximum of 15 years using the aforementioned 
Poisson model and projected estimates of the population. Results of the prediction 
model are displayed in Appendix Figure 1.  
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Appendix 2, Figure 1. Expected decrease (solid line) and 95% conﬁdence intervals (dashed) in the incidence of 
invasive pneumococcal disease due to vaccine serotypes after the introduction of the seven-valent pneumococcal 
conjugate vaccine in England and Wales. Data points represents the number of cases corrected for underlying trends in 
case ascertainment pre (average 2000-2006) and the post-seven-valent pneumococcal conjugate vaccine vaccination 
incidence
1
. 
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Appendix 3: Vaccine efficacy 
Studies have shown that both antibody responses and opsonic activity in adults are as 
high or higher after vaccination with the pneumococcal conjugate vaccines than after 
vaccination with the 23-valent vaccination for the serotypes included in both vaccine 
formulations3. Also young age could be associated with a more pronounced immune 
response4, 5. Immunogenicity studies specifically focussing on high-risk individuals such 
as the frail elderly6, HIV-infected7, 8, and transplant recipients9, 10 show no significant 
difference between vaccination with the 23-valent polysaccharide vaccine and the 
seven-valent pneumococcal conjugate vaccine , although studies focussing on other 
high-risk individuals e.g. survivors of a pneumococcal pneumonia, and allogeneic stem 
cell transplant recipients do suggest a (small) advantage of seven-valent pneumococcal 
conjugate vaccine over 23-valent polysaccharide vaccine11, 12. 
However, two clinical trials evaluating vaccine efficacy in high-risk groups show a 
favourable efficacy estimates for the pneumococcal conjugate vaccines. Both studies 
looked at HIV-infected individuals, one focussed on adults13 while the other focussed on 
infants14. The first one included 496 adult Malawi patients, who had recovered from 
documented invasive pneumococcal disease, of which 88% were HIV-positive. The 
efficacy of the seven-valent pneumococcal conjugate vaccine against invasive 
pneumococcal disease after 2 doses during the entire follow-up period (median 1.2 
years) in HIV-infected adults was estimated at 74% (95% confidence interval [CI], 30-90), 
but decreased after the first year from 85% to 25%. In contrast a study comparing the 
23-valent polysaccharide vaccine with a placebo in HIV infected adults with similar 
clinical endpoints showed no clinical benefit of the 23-valent polysaccharide vaccine15. 
Another study performed in South Africa evaluated the efficacy of 3 doses of the 9-valent 
conjugated pneumococcal  vaccine in both children with and without HIV infection14. The 
efficacy against the first episode of invasive pneumococcal disease  among HIV-infected 
infants was 65% (95% CI, 24-86) compared to 83% (95% CI, 39-97) in children without 
HIV infection. Also in HIV-infected children the efficacy attenuated faster during 5 years 
of follow-ups 38.8% (95% CI, -7.8-65.2) compared with uninfected children 77.8% 
(95%CI 34.4-92.5)16. Furthermore, this trial also evaluated the efficacy against the first 
episode if radiological confirmed alveolar consolidation (note that this is a measure of all-
cause pneumonia, not specific to the pneumococcus). In HIV infected children the point 
estimate was 13%(95% CI, -7-29), while in non infected children the efficacy was 20%.  
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In conclusion, immunogenicity data for conjugated pneumococcal vaccines show 
generally better results than the 23-valent polysaccharide vaccine in non-
immunosupressed adults, while in adults with specific underlying conditions no or only 
small advantages are observed for the seven-valent pneumococcal conjugate vaccine 
over the 23-valent polysaccharide  vacccine . Nevertheless, a clinical trial showed that 
conjugated pneumococcal vaccine is effective in HIV-infected adults, while the 23-valent 
polysaccharide vaccine failed to demonstrate efficacy in a similar study. Also, the nine 
valent pneumococcal vaccine was shown to be effective in HIV-infected infants, although 
the vaccine efficacy was lower compared to those without HIV infection. It is however 
uncertain if these efficacy estimates will also apply for developed countries in which the 
invasive pneumococcal disease  incidence is lower and HAART therapy is generally 
available3. Furthermore, it should be noted that these studies used multiple doses of the 
conjugated vaccine.  
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Appendix 4: Elicitation of vaccine efficacy estimates 
We performed a formal elicitation of expert opinions on vaccine related parameters to 
construct a probability distribution that represent the experts’ knowledge and uncertainty. 
The aim of the elicitation were to estimate efficacy and the level of waning immunity after 
vaccination with the13-valent pneumococcal conjugate vaccine in both high-risk 
immunocompromised and high-risk immunocompetent individuals aged less than 65 
years or more than 65 years of age after one (one dose was used in the base case 
analysis) or two doses of the vaccine 
The level of waning immunity was calculated by letting the experts estimate the vaccine 
efficacy during the first and third year after vaccination. Based on the difference in 
vaccine efficacy between these years the annual waning rate was calculated assuming 
an exponential decay of immunity.  
A questionnaire covering these areas was designed using an iterative process involving 
trials on three test subjects and modifications to the questionnaire based on test subject 
feedback. We recruited five experts of the Pneumococcal Subcommittee  of the Joint 
Committee on Vaccination and Immunisation to undertake the elicitation process, as it is 
known that there is little additional benefit in combining expert judgments from more than 
4 or 5 experts17. The experts were provided with background information on the question 
topics, the aims of the study, and the questionnaire by email.  
Probability distributions were elicited using the quartile/probability technique, where each 
expert separately specified their median, lower, and upper quartile estimate17. After the 
initial elicitation, distributions were fitted to the estimations and experts were given the 
opportunity to revise their estimations if they thought this was necessary after comparing 
their estimate with those of the other experts. Subsequently, the obtained experts 
distributions were combined mathematically using the method of (linear) opinion pooling. 
A beta distribution was chosen to fit to the experts’ responses as this distribution is 
defined on the interval (0,1) and therefore suitable for quantifying uncertainty in 
probabilities. To obtain the distributions we used the Sheffield Elicitation Framework 
(SHELF, v2.0 www.tonyohagan.co.uk/shelf/).  
The result of the elicitation can be found in Table 1 of the main paper for the base-case 
analysis (after a single dose of the 13 valent pneumococcal conjugated vaccine) and the 
results after two doses of the 13 valent pneumococcal conjugated vaccine can be found 
in table 1.  
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Appendix 4, Table 1. Average vaccine efficacy after two doses of 13-valent pneumococcal conjugate vaccine during 
the first year of vaccination 
Type of disease Invasive pneumococcal disease Non-bacteraemic pneumococcal pneumonia 
Immunostatus Immunocompetent Immunocompromised Immunocompeten
t 
Immunocompromised 
Age (in years) 2-65 ≥65 2-65 ≥65 2-65 ≥65 2-65 ≥65 
Vaccine efficacy$ 85% 74% 68% 54% 56% 46% 41% 32% 
$ Efficacy estimates do not apply for serotype 3 (see method section) 
16
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Appendix 5: Life expectancy among high-risk groups 
The Figure below shows the survival curves for the high-risk immunocompromised 
population, high-risk immunocompent, the general population based on the RCGP data 
collected for the years 2005 to 2010. These data were used to calculate different 
background life expectancies. The Royal College of General Practitioners (RCGP) data 
was validated by comparing the calculated survival curves with the survival curve of the 
general population based on mortality data obtained from the Office for National 
Statistics (ONS) for the year 20082.  
  
Appendix 5, Figure 1. Survival curves for individuals at different risk of developing invasive pneumococcal disease and 
the general population. Data taken from Royal College of General Practitioners database and compared with the 
survival curve for the general population obtained from the Office for National Statistics
2
. 
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Appendix 6: Used ICD-10 codes to identify possible acute pneumococcal disease 
 
A40.3 Septicaemia due to Strep Pneumoniae 
A40.8 Other streptococcal septicaemia 
A40.9 Strep. Septicaemia non specified 
A41.9 Septicaemia, unspecified 
A49.1 Streptococcal unspecified 
A49.9 Bacterial infection, unspecified 
B95.3 Step pneum as the cause of disease classified in other chapters 
B95.4/B95.5 Streptococcus as the cause of disease classified in other chapters 
G00.1 Pneumococcal meningitis 
G00.8 Other bacterial meningitis 
G00.9 Bacterial meningitis unspecified 
G04.2 Bacterial meningoencephalitis and meningomyelitis not elsewhere classified 
G04.8 Other encephalitis, myelitis and encephalomyelitis  
G04.9 Encephalitis, myelitis and encephalomyelitis, unspecified 
G05.0 Encephalitis, myelitis and encephalomyelitis in bacterial diseases classified elsewhere 
I33.0 Acute and subacute infective endocarditis 
J00 Acute Nasopharyngitis 
J01 Acute sinusitis 
J02.0 Acute pharyngitis Streptococcal 
J02.9 Acute pharyngitis, unspecified 
J03.0 Streptococcal tonsillitis 
J03.9 Tonsillits unspecified 
J04 Acute Laryngitis and tracheitis 
J05 Acute obstructive laryngitis 
J06 Acute upper respiratory infections of multiple and unspecified sites 
J13 Pneumonia due to Streptococcus pneumoniae 
J15.9 Bacterial pneumonia, unspecified 
J18 Pneumonia, organism unspecified 
J20.2 Acute Bronchitis due to streptococcus 
J20.9 Acute bronchitis, unspecified 
J21.8 Acute Bronchiolitis other specified 
J21.9 Acute Bronchiolitis, unspecified 
J22 Unspecified acute lower respiratory infection 
J86 Pyothorax 
M00.1 Pneumococcal arthritis and polyarthritis 
M00.2 Other streptococcal arthritis and polyarthritis 
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Appendix 7: Annual vaccine coverage of 23-valent vaccination  
Appendix 7, table 1.Proportion of patients annually vaccinated by risk groups with the 23 valent pneumococcal 
polysaccharide as measured in the 2009 data extract from Generals Practitioners Practices’ IT systems. 
Age group (years) 2-15 16-65 65 + 
One or more Risk Group(s) 4.1% 1.5% 7.2% 
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Appendix 8: Age group specific incidence of invasive pneumococcal disease 
 
Appendix 8, table 1. Invasive pneumococcal disease incidence per 100,000 population per risk- and age-group for 
the epidemiological year 2009-10. 
 
Risk type 
Age groups 
2-4y 5-14y 15-44y 45-64y ≥65y 
Any risk group 109.4 37.5 24.7 57.5 43.5 
splenic dysfunction 44.2 15.2 7.4 17.2 10.8 
Chronic Respiratory Disease 118.8 40.8 54.5 127.1 83.0 
Chronic Heart Disease 38.7 13.3 22.5 52.4 48.9 
Chronic Kidney Disease 110.1 37.8 21.2 49.5 14.0 
Chronic Liver Disease 277.6 95.3 108.1 252.0 116.9 
Diabetes 35.5 12.2 14.9 34.7 38.0 
Immunocompromised 384.2 131.9 55.6 129.5 190.6 
HIV Infection 945.7 324.7 198.9 463.4 86.2 
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Appendix 9 Definition of the risk groups in ICD-10 codes 
Overview of the used ICD-10 codes to identify risk group. Where possible the lowest specificity was used; e.g. only a 
letter includes all codes in the corresponding chapter.  
Risk group Used ICD codes 
Chronic respiratory disease   J40,J41,J42,J43,J44,J47,J6,J7,J80,J81,J82,J83,J84,Q30,J31,Q32,Q
33Q34,Q35,Q36,Q37 
Chronic heart disease  I05,I06,I07,I08,I09,I11,I12,I13,I20,I21,I22,I25,I27,I28,I3,I40,I41,I42,I43
,I44,I45,I47,I48,I49,I50,I51,I52,Q2 
Chronic kidney disease  N00,N01,N02,N03,N04,N05,N07,N08,N11,N12,N14,N15,N16,N18,N1
9,N25,Q60,Q61 
Chronic liver disease  K70,K71,K72,K73,K74,K75,K76,K77,P78.8,Q44 
Diabetes E10,E11,E12,E13,E14,E24,G59.0,G63.2,G73.0,G99.0,N08.3,O24, 
P70.0,P70.1,P70.2 
Immunosuppression  Malignancies affecting the immune system: 
C81,C82,C83,C84,C85,C88,C90,C91,C92,C93,C94, 
C95,C96 
HIV: 
B20,B21,B22,B23,B24 
Transplantations: 
Z94,Z85 
(Bone marrow transplants: Z94.8) 
Conditions affecting the immune system: 
D56.1,D57.8,D57.0,D57.D61,D70,D71,D72,D73,D76,D80,D81,D82D
83,D84, 1,K90.0 
Asplenia or dysfunction of the spleen  D73,D56.1,D57.8,D57.0,D57.1,K90.0 
Individuals with cochlear implants  Z96.1 
Individuals with cerebrospinal fluid leaks  G96.0 
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